NovoThirteen
catridecacog · Novo Nordisk A/S
AUTHORISED IN THE EUWhat NovoThirteen is used for
Long-term prophylactic treatment of bleeding in adult and paediatric patients 6 years and above with congenital factor-XIII-A-subunit deficiency.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- NovoThirteen
- Active substance
- catridecacog
- Disease area
- Blood Coagulation Disorders, Inherited
- Medicine group
- Antihemorrhagics
- ATC code
- B02BD11
- Marketing authorisation holder
- Novo Nordisk A/S
- Authorised in the EU since
- 2012
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is NovoThirteen used for?
Long-term prophylactic treatment of bleeding in adult and paediatric patients 6 years and above with congenital factor-XIII-A-subunit deficiency.
What is the active substance in NovoThirteen?
NovoThirteen contains catridecacog.
Who makes NovoThirteen?
The EU marketing authorisation holder is Novo Nordisk A/S.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU